Cladribine in the treatment of hairy cell leukemia: Initial and subsequent results

Leukemia and Lymphoma

Volumn 50, Issue SUPPL. 1, 2009, Pages 12-17

  Huynh, Edward ^a   Sigal, Darren ^a   Saven, Alan ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

2 CDA; Cladribine; Hairy cell leukemia

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; PENTOSTATIN; PURINE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

B LYMPHOCYTE; BACTERIAL INFECTION; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG MECHANISM; FEBRILE NEUTROPENIA; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA REMISSION; LYMPHOPROLIFERATIVE DISEASE; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; RECURRENT INFECTION; RETREATMENT; REVIEW; SECOND CANCER; SINGLE DRUG DOSE; SPLENOMEGALY;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CLADRIBINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA, HAIRY CELL; MODELS, BIOLOGICAL; NEOPLASM, RESIDUAL; PURINES;

EID: 70449433722     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802588360     Document Type: Review

References (27)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958;13:609-629.
2. Schrek R, Donnelly WJ. "Hairy" cells in blood in lymphoreticular neoplastic disease and "flagellated" cells of normal lymph nodes. Blood 1966;27:199-211.
3. Giblett ER, Anderson JE, Cohen F, et al. Adenosinedeaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972;2:1067-1069.
4. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinasemediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980;77:6865-6869.
5. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 1995;13:974-982.
6. Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Eng JMed 1990;322:1117-1121.
7. Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-1926.
8. Estey EH, Kurzrock R, Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CDA). Blood 1992;79:882-887.
9. Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): Relation to opportunistic infections. Blood 1992;79:888-894.
10. Hoffman MA, Janson D, Rose E, et al. Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 1997;15:1138-1442.
11. Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-term follow-up of the Northwestern University experience. Blood 1996;88:1954-195912.
12. Dearden CE, Matutes E, Hilditch BL, et al. Long-term followup of patients with hairy cell leukemia after treatment with pentostatin or cladribine. Br J Haematol 1999;106:515-519.
13. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-896.
14. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995;989-995.
15. Lauria F, Bocchia M, Marotta G, et al. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: A new treatment schedule effective and safer in preventing infectious complications. Blood 1997;89:1838-1839.
16. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: Final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007;109:3672-3675.
17. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C Protocol mechanism of the National Cancer Institute: A report of 979 patients. J Clin Oncol 1998;16:3007-3015.
18. Saven A, Burian C, Adusumalli J, et al. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999;93:2471-2477.
19. Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol 1997;15:1803-1810.
20. Au WY, Klasa RJ, Gallagher R, et al. Second malignancies in patients with hairy cell leukemia in British Columbia: A 20-year experience. Blood 1998;92:1160-1164.
21. Kampmeier P, Spielberger R, Dickstein J, et al. Increased incidence of second neoplasms in patients treated with interferon a 2b for hairy cell leukemia: A clinicopathologic assessment. Blood 1994;83:2931-2938.
22. Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999;17:2454-2460.
23. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term followup of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96:2981-2986.
24. Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84:4310-4315.
25. Wheaton S, Tallman MS, Hakimian D, et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996;87:1556-1560.
26. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107:4658-4662.
27. Sigal D, Sharpe RW, Burian C, et al. Potential curability of cladribine in selected patients with hairy cell leukemia [abstract]. J Clin Oncol 2008;(Suppl): Abstract 18010